Scheriproct is commonly used to provide supportive symptomatic relief, addressing specific symptoms and distressing manifestations associated with certain anorectal conditions. This approach assists with managing episodic discomfort and supports comfort during acute symptomatic phases.

Symptomatic Management of Acute Flare-ups

The medicine is commonly used for the symptomatic relief of conditions such as haemorrhoids (piles) and pruritus ani (anal itching), often recommended for short-term assistance. The medicine is also relevant in managing symptoms related to anal fissures and proctitis. It is applied across domains where short-term symptomatic assistance is needed, helping to address groups of symptoms that may appear suddenly or intensify over time.

“This supportive action contributes to easing the overall symptom load and may assist with maintaining functional stability.”

Relief for Challenging Discomfort and Disruptive Manifestations

Scheriproct is relevant in contexts marked by increased discomfort or tension, helping to manage the pronounced symptoms of pain, inflammation, swelling, and burning. It plays a role in managing symptoms related to inflammatory or irritative states that interfere with daily comfort. This supportive action contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations during periods when symptoms are more noticeable. It is applicable across conditions characterized by episodic or fluctuating manifestations.

Quick Fact: Relief for Acute Discomfort

Who Can and Cannot Use Scheriproct?

Regulatory documentation strictly defines the eligibility for Scheriproct (Prednisolone Hexanoate/Cinchocaine Hydrochloride) based on patient health status, age, and physiological condition.

Absolute Contraindications (Must Not Use)

Use is prohibited for patients with a known hypersensitivity to the active ingredients or excipients. Scheriproct is also contraindicated if there are viral infections (such as herpes or shingles), tuberculous, or syphilitic processes in the area to be treated. It must not be used in the presence of any untreated bacterial, viral, or fungal infections.

Eligibility by Age and Physiological State

The medicine is contraindicated during the first trimester of pregnancy. For the second and third trimesters and during lactation, use is not recommended unless a careful review of benefits versus risks is performed, and large-area or prolonged use must be avoided. In infants and small children, long-term continuous therapy must be avoided due to the risk of systemic absorption.

Conditional Use and Restrictions

Patients with bacterial or fungal infections may only use Scheriproct if they are concurrently receiving additional specific therapy to treat the infection. Use is restricted in patients co-administering certain CYP3A inhibitors (e.g., HIV medicines) and requires careful monitoring or avoidance, as directed by official guidance.

Interactions with other medicines and products — official regulatory information for Scheriproct

This section summarizes the officially documented interaction profile based on regulatory documentation for the combination product containing Prednisolone Hexanoate and Cinchocaine Hydrochloride.

Category	Official Regulatory Statement
Medicinal product categories with documented interactions:	Strong CYP3A Inhibitors.
Specific interacting medicines (if explicitly listed):	Ritonavir and Cobicistat (or cobicistat-containing products).
Mechanistic basis of interactions (only if stated in label):	Decreased clearance of the corticosteroid component (Prednisolone).
Timing-based interaction rules (if applicable):	None documented for medicinal product co-administration.
Interaction-related restrictions:	Concomitant use with latex products (such as condoms) may lead to reduced effectiveness of the latex product due to excipients (hard fat, castor oil).

Official interaction statements:

• Co-administration with medicines that are potent CYP3A inhibitors, specifically ritonavir and cobicistat, is expected to decrease the clearance of the corticosteroid component, Prednisolone, leading to increased systemic exposure and potential systemic side-effects.
• The hard fat and castor oil excipients contained in the rectal preparation may reduce the functional effectiveness of concurrent latex products, including condoms, which is a physical interaction.

Connection to the overall interaction profile:

Regulatory documents define the product's interaction structure through a pharmacokinetic interaction concerning the decreased clearance of the Prednisolone component when co-administered with CYP3A inhibitors. A second, non-metabolic, procedural interaction constraint is established regarding the physical compatibility of excipients with latex products as a documented risk.

Scheriproct operates through the distinct pharmacodynamic actions of its two active components, prednisolone caproate and cinchocaine hydrochloride, localized to the anoperineal tissue.

Prednisolone caproate functions as a synthetic glucocorticoid agonist. Following hydrolysis in the tissue to the active moiety, prednisolone, it translocates across the cell membrane to bind to the cytosolic glucocorticoid receptor (GR). This ligand-receptor complex subsequently translocates to the nucleus, where it acts as a transcription factor, primarily via binding to glucocorticoid response elements (GREs). This genomic mechanism modulates the transcription of specific genes, resulting in the upregulation of anti-inflammatory mediators like annexin-A1 (lipocortin-1) and the repression of genes encoding pro-inflammatory cytokines (e.g., IL-1, TNF-alpha) and enzymes like cyclooxygenase (COX) and phospholipase A2 (PLA2).

Cinchocaine hydrochloride, a local anesthetic, is a non-selective inhibitor of voltage-gated sodium channels (NaV). The agent binds to a receptor site within the inner pore of the neuronal NaV channels, stabilizing them in an inactive state. This inhibition prevents the influx of sodium ions, thereby arresting the depolarization necessary for the generation and propagation of action potentials along the afferent nerve fibers.

The administration of Scheriproct follows a two-phase treatment protocol for topical and rectal application.

Administration Scope

Feature	Instruction
Route of administration	Topical (to the perianal area) and Rectal (insertion) using the Ointment or Suppositories.
Dosing schedule (Initial Phase)	A small amount of ointment or one suppository applied two to three times daily. May be increased to four times on the first day for severe symptoms.
Dosing schedule (Maintenance Phase)	Frequency is reduced to once daily after acute symptoms have eased.
Timing in relation to meals	Not applicable. Application is typically recommended after defecation (a bowel movement).
Age-group administration rules	Use is not recommended for children and adolescents under 16 years of age.
Special procedural conditions	The total treatment duration must not exceed two weeks. The ointment requires an accompanying cannula for internal application.
Missed-dose rules	Continue the regimen at the usual time; do not use a double dose to compensate.

Connection to the overall use protocol

These instructions structure the use of the medicine as a short-term, locally applied therapy. The protocol mandates a higher initial frequency to be tapered to a once-daily maintenance dose, and is strictly constrained by a 14-day maximum duration. This defines the administration pattern and is not a recommendation for long-term use.

Research Evidence / Overview of Studies

---

Research Focus and Initial Assessment

Research efforts primarily focused on evaluating the drug's clinical profile. The primary clinical trials investigated the drug's effect on pain and inflammation associated with conditions such as hemorrhoids, anal fissures, and proctitis. Scheriproct is a combination product containing prednisolone hexanoate, a topical corticosteroid, and cinchocaine hydrochloride, a local anesthetic.

Some research included comparisons to other widely studied pharmacological agents in the trial design, and the studies investigated the duration of observed changes in symptoms. Clinical trials recorded the time points when researchers noted the first appearance of symptom changes in participants.

---

Assessment in Chronic Conditions and Subgroups

Studies assessed whether the medication was associated with participant-reported or objective measures related to movement and discomfort in participants with symptomatic anorectal conditions, with research examining its application in managing chronic inflammation.

Researchers examined the relationship between the study treatment levels and participant outcomes, which often focused on the rapid reduction of symptoms. Topical use of corticosteroids, such as prednisolone hexanoate, has been linked in research to the reduction of capillary dilation and inflammatory infiltration within tissues.

Adverse Event and Long-term Data

Studies assessed the occurrence of adverse events related to the study treatment. Clinical trial inclusion criteria generally involved participants with mild to moderate symptoms, and researchers specifically analyzed the outcome data for this participant subset.

Research protocols included the collection of adverse event data across diverse participant groups. Prolonged or excessive topical use of corticosteroids was examined for its potential association with systemic effects, although the systemic absorption of prednisolone hexanoate is considered minimal in the local application intended for this product.

Key Studies & References

1. Efficacy of a combined topical steroid and local anaesthetic preparation (Scheriproct) in the treatment of haemorrhoids and other anorectal diseases: a systematic review and meta-analysis of randomized controlled trials

Common questions about Scheriproct (FAQ)

Q: What is the official information regarding the use of Scheriproct during pregnancy?

Official regulatory information states that Scheriproct is generally contraindicated (should not be used) during the first trimester of pregnancy. For the second and third trimesters, use is generally restricted or discouraged unless a careful review of the potential benefits and risks has been performed. Regulatory documents state that prolonged or large-area use is a specific restriction to be avoided during these later stages.

Q: Is blurred vision a reported side effect of Scheriproct?

According to the official safety profile, blurred vision or other visual disturbances have been noted as a possible side effect, particularly related to the corticosteroid component. The exact frequency of this occurrence is listed as 'not known' in the regulatory documentation.

Q: How long after starting Scheriproct treatment can a person typically expect to feel initial relief?

The initial treatment protocol may involve adjustments in application frequency on the first day, which regulatory documents describe as being intended to help obtain rapid symptomatic relief at the start of treatment.

Q: How is the combination of a steroid and a local anaesthetic in Scheriproct different from single-ingredient treatments?

Scheriproct is described in regulatory documents as a dual-action agent due to its two active components. It combines the local anesthetic, cinchocaine, which provides quick relief from pain and itching, with the corticosteroid, prednisolone, which works to reduce localized inflammation and swelling.

Q: What should a patient do if their symptoms do not improve after the recommended treatment period?

The official guidance addresses situations where symptoms may not resolve. If symptoms do not improve after the recommended course duration, regulatory guidance indicates the cessation of treatment and consultation with a doctor is necessary.

Q: What happens if a person uses Scheriproct after the expiry date has passed?

Official patient information states that the medicine must not be used after the expiry date printed on the packaging. This is because using the product after the expiration date has passed may reduce its effectiveness.

Q: Does Scheriproct ointment contain any specific excipients or ingredients that might cause a skin reaction?

Regulatory documents identify specific inactive ingredients (excipients) within the ointment formulation that may cause skin reactions. These excipients, which include castor oil, hydrogenated castor oil, and macrogol 400 monoricinoleate, are noted in the official product information.

Q: Are headaches a possible side effect listed in the patient information leaflet for Scheriproct?

Headaches are not listed among the officially documented or commonly reported side effects in the regulatory patient information leaflet for Scheriproct. The safety profile focuses on potential local skin effects and risks associated with the corticosteroid component.

Q: Are there known risks if a small amount of Scheriproct is accidentally swallowed?

Official guidance addresses the risk of accidental ingestion. Swallowing a small amount of Scheriproct is generally considered unlikely to be dangerous. However, official guidance specifies that a doctor or pharmacist should be contacted if there are concerns.

Q: Is it necessary to store Scheriproct ointment in the refrigerator?

The official storage instruction for the ointment differs from that of the suppositories. Regulatory guidance states the ointment should be stored below 25 C and does not require refrigeration.

Q: What is the suggested process for cleaning the applicator nozzle after using the ointment?

The official instructions for use include guidance on applicator hygiene. After internal use, the applicator should be washed carefully, typically using hot soapy water, rinsed thoroughly, and dried before being stored.

Q: Does the ointment have a fragrance or perfume, and what is the function of this ingredient?

The ointment formulation contains a fragrance listed as perfume oil, chypre. Official product information notes that this excipient is a potential source of allergic reactions.

Q: What is the general risk of the medicine being absorbed into the bloodstream when used topically?

While the active ingredients are partly absorbed into the bloodstream after topical use, pharmacokinetic data indicates this absorption is minimal. Official safety information suggests the amount of corticosteroid delivered to the body is not high enough to cause systemic corticosteroid effects when used correctly.

Q: Are there any known interactions between Scheriproct and alcohol consumption?

The official regulatory documentation for Scheriproct is used to identify all known specific interactions. This documentation does not list any specific interactions between the product and alcohol consumption.

Q: Is the suppository or the ointment generally intended for more internal versus external use?

Official guidance distinguishes between the primary utilities of the two forms. The suppository formulation is generally intended for administration directed toward internal symptoms, while the ointment can be applied both to the external perianal area and inserted internally using the applicator.

The official storage requirements for Scheriproct differ between the two formulations and are mandatory to maintain product stability.

Formulation	Mandatory Storage Conditions
Rectal Ointment	Do not store above 25 C; replace cap tightly after use. Once opened, use within 3 months (or 4 weeks in some regions).
Rectal Suppositories	Store in a refrigerator (between 2 C and 8 C). Do not freeze.

Both the ointment and suppositories must be kept out of the sight and reach of children and must not be used after the expiry date. Unused or expired medicine must not be thrown away with household waste or wastewater. Patients must ask a pharmacist for proper disposal to protect the environment.